PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects

Q: What is the clinical evidence from this study?

Population: Conotruncal heart defects (in vitro model). Intervention: 322PESB derivative compound vs. Untreated PIP3-primed cardiomyocytes. Primary outcome: Free PIP3 concentration in PIP3 (10 nmol/L)-primed cardiomyocytes.

Q: What does this research mean for the field?

The 322PESB derivative compound acts as a PIP3 antagonist in MSC-derived cardiomyocytes, significantly altering PIP3 levels and demonstrating potential as a novel targeted molecular therapy for conotruncal heart defects. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

Alaaeldin Fayez; Nora N. Esmaiel; Haiam Abdel Raouf; Mohamad M. Aboelenin; Riham M. Aly; Ghada Nour Eldeen

doi:10.1016/j.jgeb.2026.100757

July 23, 2026Journal of Genetic Engineering and BiotechnologyOpen Access

PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects

View Full Paper

Ask AI

Bookmark

Share

Key result

322PESB derivative increases free PIP3 levels ~14-fold in primed cardiomyocytes, confirming binding antagonism.

Why the study?

Elevated PIP3 levels may contribute to conotruncal heart defects, but the efficacy of a 322PESB derivative compound as an antagonist was unknown.

Does the 322PESB derivative molecule antagonize PIP3 binding in human MSC-derived cardiomyocytes?

Key Points

To evaluate the efficacy of the 322PESB derivative compound as a molecular regulator that antagonizes PIP3 binding to the pleckstrin homology (PH) domain of Akt in mesenchymal stem cell-derived cardiomyocytes.
Isolated human adipose-derived mesenchymal stem cells (Ad-MSCs) and verified their immunophenotype (CD73, CD90, CD105, CD34, CD45) and trilineage differentiation potential according to ISCT criteria.
Differentiated hAd-MSCs into cardiomyocytes over 21 days in cardiomyogenesis-inducing medium and validated differentiation by assessing ADRB1 and MLC2a gene expression with RT-qPCR.
Treated PIP3-primed cardiomyocytes with 10 and 30 μmol/L concentrations of a 322PESB derivative molecule and measured free PIP3 concentrations via ELISA.
Flow cytometry of isolated Ad-MSCs showed high expression of CD73 (77.55%), CD90 (87.59%), and CD105 (91.88%) alongside low expression of CD34 (0.59%) and CD45 (1.78%), with differentiated cardiomyocytes displaying average increases in ADRB1 of 2.9-fold and MLC2a of 2.1-fold.
Cell viability assays showed that the viable cell count was significantly reduced by 40 μmol/L (0.003), whereas 10 and 30 μmol/L did not significantly affect cell viability.
ELISA quantification showed that treatment of PIP3 (10 nmol/L)-primed cardiomyocytes with 10 and 30 μmol/L of the 322PESB derivative significantly increased free PIP3 levels by 485.804 and 3564.164 ng/mL, respectively, compared to untreated controls.

Structured PICO

Does the 322PESB derivative molecule antagonize PIP3 binding in human MSC-derived cardiomyocytes?

P

Population

In vitro study using human adipose-derived mesenchymal stem cells from donors aged 27-43 years, differentiated into cardiomyocyte-like cells to model conotruncal heart defects.

I

Intervention

322PESB derivative molecule (10 and 30 μmol/L) applied to PIP3-primed cardiomyocytes for 24 hours.

C

Comparator

Untreated control (non-primed cardiomyocytes) and PIP3-primed cardiomyocytes without the 322PESB derivative.

O

Outcome

Intracellular free (unbound) PIP3 levels measured by ELISA assay.surrogate

Main Result

Absolute Event Rate: 3564.164% vs 252.3%

The 322PESB derivative successfully antagonizes PIP3 binding to Akt in MSC-derived cardiomyocytes, suggesting potential as a targeted molecular therapy for conotruncal heart defects.

Limitations

In vitro study design requiring further functional animal models and clinical phase studies to confirm therapeutic efficacy.
Stem cell-derived cardiomyocytes exhibit an embryonic/fetal phenotype rather than a mature adult phenotype.
In vitro model
Lack of functional animal models and clinical phase studies

Implication

322PESB antagonizes PIP3 in MSC-derived cardiomyocytes; hypothesis-generating for conotruncal heart defect therapies, pending in vivo confirmation.

Abstract

Conotruncal heart defects (CTDs) account for approximately one-third of all congenital heart defects. Elevated levels of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) may contribute to CTD pathogenesis. PIP3 plays a pivotal role in mechanotransduction-based biological processes and remodeling of cardiac cytoskeletal proteins. Here, we aimed to evaluate the efficacy of the 322PESB derivative compound as a molecular regulator that antagonizes PIP3 binding pleckstrin homology (PH) domain of the Akt protein using mesenchymal stem cell-derived cardiomyocyte. Human adipose-derived MSCs (Ad-MSCs) were isolated. Immunophenotypic features of the hAd-MSCs were characterized according to minimal criteria of the international society for cellular therapy (ISCT) including immunophenotyping and trilineage differentiation potential. Subsequently, the differentiated hAd-MSCs were cultured in cardiomyogenesis-inducing medium. Successfully differentiated cardiomyocytes were assessed by measuring the expression levels of cardiomyocyte-specific genes using RT-qPCR. PIP3-primed cardiomyocytes were treated with 10 and 30 μmol/L of a 322PESB derivative molecule. The results showed a typical MSCs with high expression levels of CD73 (77.55%), CD90 (87.59%) and CD105 (91.88%) and that was accompanied by low expression levels of CD34 (0.59%) and CD45 (1.78%). After 21 days of MSC culture, cardiomyocyte-like cells with prominent striations were observed. Subsequent confirmation by RT-qPCR quantification of ADRB1 and MLC2a expression levels showed an average increase of 2.9-fold and 2.1-fold, respectively, in induced cardiomyocytes. Compared with the untreated control, PIP3 ELISA assay showed a significant increase in PIP3 levels in PIP3(10 nmol/L)-primed cardiomyocytes treated with 10 and 30 μmol/L of the 322PESB molecule derivative by 485.804 and 3564.164 ng/mL, respectively. In this study, we conducted the first promising molecular regulator with potential therapeutic implications for CTD patients. Further functional animal model and clinical phase studies are recommended.

Discussion

No takes yet. Share an insight, caveat, or question.

Figures from the paper

Published by Journal of Genetic Engineering and Biotechnology · CC BY-NC-ND

Cite This Study

Fayez et al. (2026) studied Conotruncal heart defects (in vitro model). 322PESB derivative compound vs. Untreated PIP3-primed cardiomyocytes was evaluated on Free PIP3 concentration in PIP3 (10 nmol/L)-primed cardiomyocytes. Treatment of PIP3 (10 nmol/L)-primed cardiomyocytes with 10 and 30 μmol/L of the 322PESB derivative significantly increased free PIP3 levels to 485.8 and 3564.2 ng/mL, respectively, indicating successful antagonism of PIP3 binding.

synapsesocial.com/papers/6a65a36cd3aea3239cd768f2 https://doi.org/10.1016/j.jgeb.2026.100757

View Full Paper

Ask AI

Bookmark

Share

PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects

Key Points

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects

Key Points

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

Keep reading

Keep reading